

Role of Beta-Blockers Following Percutaneous Balloon Pulmonary Valvuloplasty

Thesis

Submitted for Partial Fulfillment of Master Degree in Cardiology

By

Mohamed Ashraf Abdelsabour Abdelazeem M. B. B. Ch.

Supervised by

Prof. Dr. Ghada Samir El-Shahid

Professor of Cardiology Faculty of Medicine – Ain Shams University

Prof. Dr. Alaa Mahmoud Roushdy

Professor of Cardiology Faculty of Medicine – Ain Shams University

Dr. Tarek Khairy Moussa

Lecturer of Cardiology
Faculty of Medicine – Ain Shams University

Faculty of Medicine
Ain Shams University
2018



سورة البقرة الآية: ٣٢

Acknowledgment

The vision for this thesis could only become a reality today because of the kind help and support of many; I would like to take the opportunity to extend my gratitude to them all.

First and foremost, all praise is to ALLAH Almighty for his daily blessings, beyond count or description, and beyond all attempts of thanks and gratitude.

For their relentless and continuous guidance, I am grateful to my supervisors. Their support and luminous feedback provided the backbone of this thesis.

I wish to express my deepest gratitude to Prof. Dr. Ghada Samir

El-Shahed, Professor of Cardiology, Faculty of Medicine, Ain Shams University, for her invaluable mentorship and for her unremitting leadership, evident at every step of this work. It has been an honor to complete this thesis under her direction.

I'm deeply indebted to **Dr. Alaa Mahmoud Roshdy,** Professor of Cardiology, Faculty of Medicine, Ain Shams University, for his priceless scientific assistance and the invaluable effort he provided during his supervision of this work.

I am delighted to have had **Dr. Tarek Khairy Mousa**, Lecturer of Cardiology, by my side during this endeavor, both as a mentor and as a friend.

My heartiest gratitude goes, of course, to my father and mother, always paving the path before me, never ceasing to believe in me. My past and my future are shaped by the warmth of your support.

To my wife, for her passionate encouragement and steadfast support.

My thanks also go to my brother and sister, my friends and my colleagues for their continuous support throughout my life.

Finally, I humbly extend my thanks to the patients who participated in this research, my department and to the great institution of Ain Shams University.

List of Contents

Title	Page No.
List of Tables	5
List of Figures	7
List of Abbreviations	10
Introduction	1
Aim of the Work	14
Review of Literature	
Pulmonary Stenosis	15
Balloon Pulmonary Valvuloplasty	32
 Infundibular Hypertrophy and Beta-Blockers 	s45
Patients and Methods	52
Results	66
Discussion	84
Limitations and Recommendations	92
Conclusion	93
Summary	94
References	96
Archie Summary	

List of Tables

Table No.	Title	Page	No.
Table (1):	Overview of the pharmacological pharmacokinetic characteristics of the blockers	he β-	46
Table (2):	Demographic and anthropometric date the Placebo arm and the BB arm		66
Table (3):	Procedural data for the Placebo arm the BB arm	and	
Table (4):	Comparison between placebo arm an arm regarding functional capacity echocardiographic data at 24 hours BPV	and post-	69
Table (5):	A Comparison between placebo arm BB arm regarding functional capacity echocardiographic data at 1 month	and and post-	
Table (6):	BPVA comparison regarding functional cap and echocardiographic data obtained hours and at 1 month post-BPV fo	oacity at 24 r the	
Table (7):	A comparison regarding functional cap and echocardiographic data obtained hours and at 1 month post-BPV for the	pacity at 24 ne BB	
Table (8):	A comparison between the two study regarding the percent change between and echocardiographic data obtained	arms n FC at 24	
Table (9):	hours and at 1 month after BPV Correlation of age and B/A ratio percentage of change in FC	with and	
Table (10):	echocardiographic data in placebo Arm Correlation of participant sex with percentage of change in FC	the the	80
	echocardiographic data in placebo Arm		81

List of Cables Cont...

Table No.		Title		Page No.
Table (11):		of age and		
Table (12):	Correlation	raphic data ir of participa of change	int sex wit	
		U		ани 83

List of Figures

Fig. No.	Title P	age	No.
Figure (1):	Drawing of pulmonary stenosis with a septal defect and left to right shunt	well	
Figure (2):	depicting the case of a 16-year-old reported by Morgagni	from valve the	15
T! (0)	plication of the arterial wall at sinutubular junction. (c) Dome-shaped with shallow sinuses (s)	valve	17
Figure (3):	(a) Dome-shaped valve with dyspl leaflets (b) Histologic section shows fit dysplasia of the edge of the leaflets the thinner component proximally (c) sinutubular junction (arrowhead)	rous out a The	
	markedly accentuated in this section to close to the raphé		
Figure (4):	Fusion of the adjacent leaflets along commissures in valvular pulmo stenosis	their nary	
Figure (5):	Right atrial abnormality is so obverthat the amplitude of the P wave in II is above than that of the following complex	vious lead QRS	
Figure (6):	ECG showing right axis deviation right ventricular hypertrophy	and	
Figure (7):	Chest radiograph reveals dilatation of main pulmonary artery with relat normal-sized right and left pulmo	f the ively nary	
Figure (8):	The thickened domed PV leaflets in the	e RV	
	outflow view	•••••	∠8

List of Figures Cont...

Fig. No.	Title	Page	No.
Figure (9):	The echo shows post-stenotic dilation pulmonary trunk		
Figure (10):	Continuous wave spectral Doppler		
(the pulmonary valve demonstrates velocity of flow, and calculated instantaneous and mean gradients the valve	a high peak across	
Figure (11):	Right ventricular outflow tract angi-	ogram,	
G	demonstrating the domed and st pulmonary valve, and al measurement of the ventriculo-a junction	enosed lowing arterial	
Figure (12):	Right ventriculogram in antero-poste		
•	Lateral projection showing an angio		
	balloon partially inflated acros pulmonary valve, with the charact hourglass impression imposed o balloon by the stenosed pulmonary	s the teristic n the valve	
E: (1.4).			
rigure (14):	Mechanism of Beta-blockers acti		
Eigene (15).	myocytes Parasternal short axis view to m		
rigure (19):	pulmonary valve annulus and MPA.		
Figure (16):	Suprasternal crab view to measure R		
Figure (17):	Parasternal short axis view to	assess	
	severe PR		56
Figure (18):	The RV dimensions measuremen	t and	
	tricuspid valve annulus measurem	ent in	
	the apical four chamber view		57
Figure (19):	RV volume measurement at end-dias	tole	58
Figure (20):	RV volume measurement at end syst	ole	59

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (21):	Upper panel shows tracing to diastolic area of the RV in cm 2 a panel shows tracing the end systolic the RV to calculate the ECG gated	nd lower ic area of
Figure (22):	TAPSE measurement	
Figure (23):	The peak pressure gradient (15 across the PV recorded using CW I	•
Figure (24):	A comparison regarding functional and echocardiographic data obtain hours and at 1 month post-BPV placebo arm.	capacity ned at 24 for the
Figure (25):	A comparison regarding functional and echocardiographic data obtain hours and at 1 month post-BPV fo	capacity ned at 24 or the BB
Figure (26):	A comparison between the two sturegarding the percent change is obtained at 24 hours and at 1 more BPV.	udy arms n RVOT nth after
Figure (27):	A comparison between the two sturegarding the percent change obtained at 24 hours and at 1 more BPV.	ıdy arms in PG nth after

List of Abbreviations

Full term Abb. 2D.....Two-dimensional ACAdenylate cyclase ATP.....Adenosine triphosphate AVAtrio-venticular BB.....Beta-blockers BPV.....Balloon pulmonary valvuloplasty BSA.....Body surface area Ca2+.....Calcium cAMPCyclic adenosine monophosphate CRF.....Case report form ECGElectrocardiogram EDVEnd diastolic volume ESV.....End systolic volume FAC.....Fractional area change ICF.....Informed consent form ISA.....Intrinsic sympathomimetic activity L-VDCCL-type or voltage-gated calcium channel MPA.....Main pulmonary artery MSAMembrane stabilizing activity PAPulmonary artery PDE.....Phosphodiesterase PKA.....Protein kinase A PLAXParasternal long axis PS.....Pulmonary stenosis PRPulmonary regurgitation PSAX.....Parasternal short-axis RVOT.....Right ventricular outflow tract



RVOTORight ventricular outflow tract obstruction

List of Abbreviations Cont...

Full term Abb. RPA.....Right pulmonary artery RV.....Right ventricle RVHRight ventricle hypertrophy RVOT.....Right ventricle outflow tract RVOTORight ventricular outflow tract obstruction RyRRyanodine receptor SDStandard deviations TAPSETricuspid annular plane systolic excursion TRTricuspid regurgitation VA.....Ventriculo-arterial

INTRODUCTION

Vongenital heart malformations are the most frequent of all major birth defects. Pulmonary stenosis (PS) accounts for approximately 8 - 12% of all congenital cardiac defects, with an incidence of about 1 per 2000 live births worldwide (Mitchell and Mhlongo, 2018).

Amongst congenital heart disease, PS is the second most common congenital cardiac malformation and is accompanied in approximately 20% of congenital heart disease cases (Yang and Yi, 2005). In Egypt, its prevalence is 2.3 per 10 000 school children (Bassili et al., 2000).

The traditional treatment for pulmonary valve stenosis prior to 1982 was surgical valvotomy. The relief of pulmonary by balloon dilatation valve stenosis during cardiac catheterization was first reported in 1982 (Kan et al., 1982). Since then, balloon pulmonary valvuloplasty has become the treatment of choice for relief of pulmonary valve stenosis (Rao et al., 2007).

It is theorized that dynamic right ventricular outflow tract obstruction plays a very crucial role in the immediate post operative period which can cause significant morbidity and mortality (Subbarao et al., 1989). A case study concerning a patient with worsening right ventricular outflow tract obstruction following BPV has emphasized the need for



preemptive hydration and beta-blocker therapy prior to balloon dilatation (Khambatta et al., 2006).

However, there is an absence of properly designed, randomized controlled trials to assess the role of routinely using beta blockers following BPV, hence the rationale of this study.

AIM OF THE STUDY

To assess the role of beta-blockers on functional capacity and cardiac hemodynamics following BPV in patients with congenital pulmonary stenosis.

Chapter 1

PULMONARY STENOSIS

The first description of pulmonary stenosis as a separate pathological entity was in 1761 by Giovanni Battister Morgagni in Padova Italy, who is generally regarded as the father of modern anatomical pathology (*Zampieri et al.*, 2016).




Figure (1): Drawing of pulmonary stenosis with atrial septal defect and left to right shunt well depicting the case of a 16-year-old girl reported by Morgagni. Note the right-to-left shunt at the level of patent foramen ovale (*Zampieri et al.*, 2016).